Cyclic AMP induced stimulation and inhibition of Ca2--uptake in rat cardiac sarcolemma vesicles.

J. Velema,G. Bolt,J. Zaagsma

DOI: https://doi.org/10.1016/0006-2952(83)90499-9

IF: 6.1

1983-02-15

Biochemical Pharmacology

Abstract:

What problem does this paper attempt to address?

On the ultraviolet absorption and the structure of motor anterior horn cells in the spinal cord from exhausted rabbits.

I. Hochberg

DOI: https://doi.org/10.1111/J.1699-0463.1958.TB01742.X

2009-08-18

Abstract:
Dissociation of vasospasm-related morbidity and outcomes in patients with aneurysmal subarachnoid hemorrhage treated with clazosentan: A meta-analysis of randomized controlled trials: A review

Jian Shen,Jianwei Pan,Zuoxu Fan,XiaoXing Xiong,Renya Zhan

DOI: https://doi.org/10.3171/2013.3.JNS121436

IF: 5.408

2013-01-01

Journal of Neurosurgery

Abstract:Object. Clazosentan therapy after aneurysmal subarachnoid hemorrhage (SAH) has been found to be effective in reducing the incidence of vasospasm in randomized controlled trials. However, while vasospasm-related morbidity, including delayed ischemic neurological deficits (DINDs) and delayed cerebral infarctions, was consistently decreased, statistical significance was not demonstrated and outcomes were not affected by clazosentan treatment. The objective of this meta-analysis was to determine whether clazosentan treatment after aneurysmal SAH significantly reduced the incidence of DINDs and delayed cerebral infarctions and improved outcomes. Methods. All randomized controlled trials investigating the effect of clazosentan were retrieved via searches with sensitive and specific terms. Six variables were abstracted after the assessment of the methodological quality of the trials. Analyses were performed following the method guidelines of the Cochrane Back Review Group. Results. Four randomized, placebo-controlled trials met eligibility criteria, enrolling a total of 2181 patients. The meta-analysis demonstrated a significant decrease in the incidence of DINDs (relative risk [RR] 0.76 [95% CI 0.62-0.92]) and delayed cerebral infarction (RR 0.79 [95% CI 0.63-1.00]) in patients treated with clazosentan after aneurysmal SAH. However, this treatment regimen was not shown to outcomes including functional outcomes measured by Glasgow Outcome Scale-Extended (RR 1.12 [95% CI 0.96-1.30]) or mortality (RR 1.02 [95%CI 0.70-1.49]). Adverse events, including pulmonary complications, anemia, and hypotension, were all significantly increased in patients who received clazosentan therapy. Conclusions. The results of the present meta-analysis show that treatment with clazosentan after aneurysmal SAH significantly reduced the incidence of the vasospasm-related DINDs and delayed cerebral infarctions, but did not improve poor neurological outcomes in patients with aneurysmal SAH. Further study is required to elucidate the dissociation between vasospasm-related morbidity and outcomes.
Cardiopulmonary Events of the Elderly (≥75 Years) during Clazosentan Therapy after Subarachnoid Hemorrhage: A Retrospective Study from a Tertiary Stroke Center in Japan

Tatsushi Mutoh,Hiroaki Aono,Wataru Seto,Takehiro Kimoto,Ryota Tochinai,Junta Moroi,Tatsuya Ishikawa

DOI: https://doi.org/10.3390/medicina60010185

2024-01-21

Abstract:Clazosentan has been shown to prevent vasospasm and reduce mortality in patients after aneurysmal subarachnoid hemorrhage (SAH) and has been approved for clinical use in Japan; however, its systemic events in the elderly (aged ≥ 75 years) have not been well-documented. Here, we report serious/intolerable cardiopulmonary complications requiring discontinuation of drug therapy in elderly SAH patients. In this single-center case series study, medical records of consecutive SAH patients treated postoperatively with clazosentan (10 mg/h) between June 2022 and May 2023 were reviewed retrospectively. Thirty-three patients received clazosentan therapy, of whom six were elderly with a mean age of 80.3 ± 5.2 (range 75-89) years. Among them, despite no obvious medical history of systemic abnormalities, clazosentan was discontinued in three (50%) patients due to pleural effusion and hypoxemia with or without hypotension at 5 ± 3 days after therapy initiation, which was higher than the incidence for younger patients (15%). The elderly patients had significantly lower urine output (1935 ± 265 vs. 1123 ± 371 mL/day, p = 0.03) and greater weight gain (2.1 ± 1.1 vs. 4.2 ± 1.9 kg from baseline, p = 0.04) than patients who completed the therapy. One 89-year-old female developed congestive heart failure and hydrostatic pulmonary edema associated with increased intravascular and lung volumes even after therapy was discontinued, while the remaining two cases recovered within 2 days after drug cessation. These results suggest that elderly patients are more vulnerable to fluid retention and have a higher risk of cardiopulmonary complications during clazosentan therapy than younger patients. Careful monitoring of urine volume and weight gain and caution regarding age- and therapy-related hemodynamic insufficiencies are required.
Factors Influencing Discontinuation of Clazosentan Therapy in Elderly Patients with Aneurysmal Subarachnoid Hemorrhage: A Retrospective Study from a Japanese Single Center

Tatsushi Mutoh,Hiroaki Aono,Wataru Seto,Takehiro Kimoto,Ryota Tochinai,Junta Moroi,Tatsuya Ishikawa

DOI: https://doi.org/10.12659/msm.943303

2024-01-03

Medical Science Monitor

Abstract:BACKGROUND Clazosentan is an endothelin receptor antagonist approved in Japan for preventing cerebral vasospasm and vasospasm-associated cerebral ischemia and infarction. This study included elderly patients aged ≥75 years with aneurysmal subarachnoid hemorrhage (SAH) and aimed to evaluate the factors associated with discontinuing anti-vasospasm therapy with clazosentan. MATERIAL AND METHODS In this single-center retrospective observational study, we extracted diagnostic and therapeutic work-up data of consecutive 40 patients with SAH treated with clazosentan infusion (10 mg/h) as first-line anti-vasospasm therapy between May 2022 and August 2023. Patient data were compared between the discontinued and completed groups, and related factors for the discontinuation were further analyzed. RESULTS Clazosentan was discontinued in 22% (n=9) of patients due to intolerable dyspnea accompanied by hypoxemia at 5±3 days after therapy initiation, in which 44% (n=4) were elderly (≥75 years). Patients who discontinued clazosentan therapy showed significantly lower urine volumes compared with those who completed the therapy (P<0.05). Multivariate regression analysis revealed that day-to-day urine volume variance and older age were independent risk factors for drug cessation (P<0.05). The cut-off value for predicting clazosentan discontinuation was -0.7 mL/kg/h with sensitivity of 86% and specificity of 75% (area under the curve: 0.76±0.10; 95% confidence interval: 0.56-0.96; P=0.035). CONCLUSIONS Our results suggest that approximately 20% of SAH patients suffered from intolerable respiratory symptoms attributable to hypoxemia. We found that both reduced day-to-day urine volume variation and older age are independent risk factors for drug discontinuation.

medicine, research & experimental
Prophylactic management of cerebral vasospasm with clazosentan in real clinical practice: a single-center retrospective cohort study

Hiroyuki Sakata,Atsushi Kanoke,Hiroki Uchida,Shinya Haryu,Shunsuke Omodaka,Naoto Kimura,Masahiro Yoshida,Kuniyasu Niizuma,Teiji Tominaga,Hidenori Endo

DOI: https://doi.org/10.3389/fneur.2024.1413632

IF: 3.4

2024-06-07

Frontiers in Neurology

Abstract:Introduction: Clazosentan, a selective endothelin receptor subtype A antagonist, reduces vasospasm-related morbidity and all-cause mortality following aneurysmal subarachnoid hemorrhage (SAH) in the Japanese population, as demonstrated by a recent randomized phase 3 trial. However, evidence to suggest clazosentan should be prioritized over the current standard of care to prevent cerebral vasospasm is still lacking. Therefore, we investigated the efficacy and safety of clazosentan in comparison with conventional postoperative management in real-world clinical practice. Methods: We conducted a single-center, retrospective, observational cohort study using prospectively collected data from consecutive patients with aneurysmal SAH. After clazosentan was approved for use in Japan, the conventional postoperative management protocol, composed of intravenous fasudil chloride and oral cilostazol (control group, April 2021 to March 2022), was changed to the clazosentan protocol (clazosentan group, April 2022 to March 2023). The primary endpoint was the incidence of vasospasm-related symptomatic infarction. The secondary endpoints were favorable functional outcomes (modified Rankin scale score < 3) at discharge, angiographic vasospasm, and the need for rescue therapy for delayed cerebral ischemia. Results: The analysis included 100 and 81 patients in the control and clazosentan groups, respectively. The incidence of vasospasm-related symptomatic infarction was significantly lower in the clazosentan group than in the control group (6.2% vs. 16%, p = 0.032). Multiple logistic analyses demonstrated that the use of clazosentan was independently associated with fewer incidence of vasospasm-related symptomatic infarct (23.8% vs. 47.5%, odds ratio 0.34 [0.12–0.97], p = 0.032). Clazosentan was significantly associated with favorable outcomes at discharge (79% vs. 66%, p = 0.037). Moreover, both the incidence of angiographic vasospasm (25.9% vs. 44%, p = 0.013) and the need for rescue therapy (16.1% vs. 34%, p = 0.006) was lower in the clazosentan group. The occurrence of pulmonary edema was significantly higher with clazosentan use (19.8% vs. 5%, p = 0.002), which did not result in morbidity. Conclusion: A postoperative management protocol centering on clazosentan was associated with the reduced vasospasm-related symptomatic infarction and improved clinical outcomes compared to the conventional management protocol in Japanese clinical practice. Clazosentan might be a promising treatment option for counteracting cerebral vasospasm after aneurysmal SAH.

neurosciences,clinical neurology
Real-world data of clazosentan in combination therapy for aneurysmal subarachnoid hemorrhage: a multicenter retrospective cohort study

Shinsuke Muraoka,Takumi Asai,Takahiko Fukui,Shinji Ota,Shinji Shimato,Naoki Koketsu,Toshihisa Nishizawa,Yoshio Araki,Ryuta Saito

DOI: https://doi.org/10.1007/s10143-023-02104-2

2023-08-09

Abstract:Aneurysmal subarachnoid hemorrhage (aSAH) may lead to cerebral vasospasm, significantly associated with morbidity and mortality. In double-blind, placebo-controlled phase 3 studies, clazosentan reduces cerebral vasospasm-related morbidity and all-cause mortality in patients with aSAH. There are no reports about the clinical efficacy of clazosentan combination therapy with some other drugs. Initially, we explored the efficacy of clazosentan combination therapy with cilostazol, statin, and antiepileptic drugs. Subsequently, we assessed the add-on effect of fasudil to clazosentan combination therapy for aSAH patients. This multicenter, retrospective, observational cohort study included Japanese patients with aSAH between June 2022 and March 2023. The primary outcome was the ordinal score on the modified Rankin Scale (mRS; range, 0-6, with elevated scores indicating greater disability) at discharge. Among the 47 cases (women 74.5%; age 64.4 ± 15.0 years) undergoing clazosentan combination therapy, 29 (61.7%) resulted in favorable outcomes. Overall, vasospasm occurred in 16 cases (34.0%), with four cases (8.5%) developing vasospasm-related delayed cerebral ischemia (DCI). Both hypotension and vasospasm-related DCI were related to unfavorable outcome at discharge. Fasudil were added in 18 (38.3%) cases. Despite adding fasudil to clazosentan combination therapy, the incidence of aSAH-related vasospasm did not decrease. Added-on fasudil to combination therapy related to pulmonary edema, vasospasm, and vasospasm-related DCI, and unfavorable outcomes. Clazosentan combination therapy could potentially result in favorable outcomes for aSAH patients to prevent post-aSAH vasospasm-related DCI. The add-on effect of fasudil to combination therapy did not demonstrate a significant impact in reducing aSAH-related vasospasm or improving outcomes at discharge.
[Anatomo-histological aspects of renal tuberculosis treated with chemioantibiotic therapy].

M. Pezza

1958-12-01

Abstract:
Comparison of efficacy between clazosentan and fasudil hydrochloride-based management of vasospasm after subarachnoid hemorrhage focusing on older and WFNS grade V patients: a single-center experience in Japan

Tatsuki Mochizuki,Bikei Ryu,Shogo Shima,Eriko Kamijyo,Koki Ito,Tamon Ando,Kazuki Kushi,Shinsuke Sato,Tatsuya Inoue,Akitsugu Kawashima,Takakazu Kawamata,Yoshikazu Okada,Yasunari Niimi

DOI: https://doi.org/10.1007/s10143-024-02345-9

IF: 2.8

2024-03-14

Neurosurgical Review

Abstract:Subarachnoid hemorrhage often leads to poor outcomes owing to vasospasm, even after successful aneurysm treatment. Clazosentan, an endothelin receptor inhibitor, has been proven to be an effective treatment for vasospasms in a Japanese randomized controlled trial. However, its efficacy in older patients (≥ 75 years old) and those with World Federation of Neurosurgical Societies (WFNS) grade V has not been demonstrated. We retrospectively evaluated the efficacy of clazosentan in older patients and those with WFNS grade V, using real-world data. Patients with subarachnoid hemorrhage treated before and after the introduction of clazosentan were retrospectively evaluated. The patients were categorized into two groups (clazosentan era versus pre-clazosentan era), in which vasospasm management and outcomes were compared. Vasospasms were managed with fasudil hydrochloride-based (pre-clazosentan era) or clazosentan-based treatment (clazosentan era). Seventy-eight patients were included in this study: the clazosentan era ( n = 32) and pre-clazosentan era ( n = 46). Overall, clazosentan significantly reduced clinical vasospasms (clazosentan era: 31.3% versus pre-clazosentan era: 60.9%, p = 0.01), delayed cerebral ischemia (DCI) (9.4% versus 39.1%, p = 0.004), and vasospasm-related morbidity and mortality (M/M) (3.1% versus 19.6%, p = 0.03). In subgroup analysis of older patients or those with WFNS grade V, no significant difference was observed in clinical outcomes, although both DCI and vasospasm-related M/M were lower in the clazosentan era. Clazosentan was more effective than fasudil-based management in preventing DCI and reducing vasospasm-related M/M. Clazosentan could be used safely in older patients and those with WFNS grade V, although clinical outcomes in these patients were comparable to those of conventional treatment.

surgery,clinical neurology
Initial clinical experience of vasodilatory effect of intra-cisternal infusion of magnesium sulfate for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage

Kentaro Mori,Takuji Yamamoto,Yasuaki Nakao,Hideo Osada,Yasukazu Hara,Kazutaka Oyama,Takanori Esaki

DOI: https://doi.org/10.2176/nmc.49.139

Abstract:The vasodilatory effect of intra-cisternal infusion of magnesium sulfate solution was evaluated in 10 patients with symptomatic vasospasm after aneurysmal subarachnoid hemorrhage (SAH) who underwent early clipping surgery. Cisternal drainage was installed in the prepontine and/or sylvian fissures. Carotid angiography was performed immediately after the onset of symptomatic vasospasm, then intra-cisternal infusion of 15 mmol/l magnesium sulfate in Ringer solution was started at 20 ml/hr and continued until day 14. Irrigation was performed from the cisternal tube (inlet) to the spinal drainage (outlet). The cerebrospinal fluid magnesium ion concentration (1.2 +/- 0.2 mEq/l) significantly increased after the infusion therapy (6.0 +/- 1.7 mEq/l, p < 0.001). Repeat angiography showed vasodilatory effect on the spastic cerebral arteries at 3 hours after the infusion, especially in the arteries near to the site of cisternal drainage placement. The magnesium infusion also caused decreased mean arterial blood velocity in the spastic arteries in 6 of the 7 measured patients (162 +/- 38 cm/sec to 114 +/- 42 cm/sec, p < 0.001). Finally, 5 of the 10 patients achieved good recovery, 1 patient had moderate disability, 1 patient became severely disabled due to meningitis, and 3 patients were vegetative or dead, due to failure of magnesium irrigation in 1 patient and advanced age in the other 2 (more than 80 years old). This preliminary study indicates that intra-cisternal infusion of magnesium sulfate solution has vasodilatory effect on the spastic cerebral arteries after aneurysmal SAH.
Symptomatic Vasospasm Refractory to Clazosentan after Subarachnoid Hemorrhage of Ruptured Vertebral Artery Dissecting Aneurysm: Clinical Implications from Two Contrasting Cases

Yasuyuki Yoshida,Tatsushi Mutoh,Junta Moroi,Tatsuya Ishikawa

DOI: https://doi.org/10.3390/medicina60091543

2024-09-20

Abstract:Clazosentan prevents vasospasms after aneurysmal subarachnoid hemorrhage (SAH). However, clinical data on patients with SAH with ruptured vertebral artery dissecting aneurysms (VADAs) are limited. We report the case of a 49-year-old male patient with mild-grade (WFNS grade 1) thick and diffuse (modified Fisher grade 3) SAH who underwent endovascular trapping of a ruptured VADA, resulting in a poor functional outcome with a modified Rankin Scale score of 4 due to severe symptomatic vasospasm refractory to clazosentan, requiring repeated rescue endovascular therapies and chronic communicating hydrocephalus. A retrospective analysis of the clot density in the basal and Sylvian cisterns, assessed by the Hounsfield unit (HU) values of serial CT scans, in this patient showed persistent higher values, distinct from another VADA case that showed a decline in HU values with a good clinical course. These results imply the limited effectiveness of clazosentan in cases of thick and diffuse SAH after a ruptured VADA, even in good-clinical-grade patients treated with less invasive modalities. The HU values may become a simple quantitative marker for predicting symptomatic vasospasms and chronic hydrocephalus.
Transient convective burning of a periodic fuel-droplet array

Guangzhi Wu,W. Sirignano

DOI: https://doi.org/10.1016/J.PROCI.2010.05.012

Abstract:
[Postoperative Management of Aneurysmal Subarachnoid Hemorrhage]

Hiroyuki Sakata,Hidenori Endo

DOI: https://doi.org/10.11477/mf.1436204998

Abstract:Delayed cerebral ischemia(DCI) is one of the most significant complications of subarachnoid hemorrhage. Despite significant evolution in understanding DCI pathophysiology, vasospasm affecting cerebral vessels of large and moderate diameters remain the only clinically measurable component of DCI and is therefore the primary target for intervention in the postoperative management of subarachnoid hemorrhage. In Japan, fasudil hydrochloride and ozagrel sodium are widely used to prevent vasospasms; however, their effects are sometimes insufficient. Clazosentan, a selective endothelin receptor subtype A antagonist, reduces vasospasm-related morbidity and all-cause mortality following aneurysmal subarachnoid hemorrhage. This was demonstrated in a recent randomized phase 3 trial, leading to the approval of clazosentan by the Pharmaceuticals and Medical Devices Agency in Japan. Recent advances in our understanding of subarachnoid hemorrhage will facilitate improved management to reduce the incidence of DCI.
REACT: a randomized trial to assess the efficacy and safety of clazosentan for preventing clinical deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage

Stephan A Mayer,Nicolas Bruder,Giuseppe Citerio,Luc Defreyne,Cecile Dubois,Rajiv Gupta,Randall Higashida,Angelina Marr,Thanh N Nguyen,Sébastien Roux,Martin Smrčka,Ramon Torné Torné,E François Aldrich,on behalf of the REACT investigators,Claudius Thomé,Andreas Gruber,Xavier Wittebole,Jacques Creteur,Johannes van Loon,Didier Ledoux,Tim Darsaut,Michael Kelly,Gwynedd Pickett,Anthony Kaufmann,Ondřej Bradáč,Martin Smrcka,Svatopluk Řehák,Tomas Hrbac,Martin Sames,Vladimir Priban,Troels Halfeld Nielsen,Peter Birkeland,Antti Ronkainen,Justiina Huhtakangas,Jaakko Rinne,Timo Koivisto,Jean-Claude Dumont,Pierre Simeone,Russell Chabanne,Anne-Claire Lukaszewicz,Thomas Ritzenthaler,Vincent Degos,Vincent Costalat,Philippe Seguin,Vincent Legros,Lionel Calviere,Etiénne Gayat,Bertrand Rozec,Manfred Westphal,Sylvia Bele,Andreas W Unterberg,Maria Wostrack,Sebastian Brandner,Ilker Eyüpoglu,Jürgen Konczalla,Nils Hecht,Stefan Wolf,Philipp Dammann,Ansgar Berlis,Angelika Ehlert,Jan Leppert,Ralph König,Jan Cornelius,Athanasios Petridis,Florian Gessler,Attila Lajgut,Pál Barzó,András Büki,Péter Tóth,Sándor Szabó,Yigal Shoshann,Levi Leon,Moshe Attia,Sagi Harnof,Marina Munari,Sandra Rossi,Anselmo Caricato,Paweł Słoniewski,Przemysław Kunert,Maciej Śniegocki,Dariusz Jaskólski,Robert Juszkat,Javier Ibanez,Alfonso Lagares,Jose Fernandez Alen,Fuat Arikan Abello,Andreu Gabarros Canals,Jesús Morera Molina,Carlos Dominguez Alonso,Fabián Romero-Chala,Ola Nilsson,Johan Ljungqvist,Oscar Aneman,Johanna Eneling,Ajith Thomas,Christopher Ogilvy,Jesse J Liu,Henry Woo,Nicholas Bambakidis,John Reavey-Cantwell,Jan Claassen,Gary Steinberg,Eric Sauvageau,Ahmed Cheema,Bappaditya Ray,Jorge Ortiz Garcia,Masoom Desai,Thanh Nguyen,Ali Alaraj,Sepideh Amin-Hanjani,Kadir Erkmen,Gregory Zipfel,Ciaran Powers,Hazem Shoirah,J Mocco,Paul Singh,Francois Aldrich,J Marc Simard,Michael Froehler,Kevin Cockroft,William Freeman,Jia Romit

DOI: https://doi.org/10.3171/2024.4.JNS232191

2024-08-09

Abstract:Objective: Ischemic complications account for significant patient morbidity following aneurysmal subarachnoid hemorrhage (aSAH). The Prevention and Treatment of Vasospasm with Clazosentan (REACT) study was designed to assess the safety and efficacy of clazosentan, an endothelin receptor antagonist, in preventing clinical deterioration due to delayed cerebral ischemia (DCI) in patients with aSAH. Methods: REACT was a prospective, multicenter, randomized, double-blind, phase 3 study. Eligible patients had aSAH secured by surgical clipping or endovascular coiling, and had presented with thick and diffuse clot on admission CT scan. Patients were randomized (1:1 ratio) to 15 mg/hour intravenous clazosentan or placebo within 96 hours of the aSAH for up to 14 days, in addition to standard of care treatment including oral or intravenous nimodipine. The primary efficacy endpoint was the occurrence of clinical deterioration due to DCI up to 14 days after initiation of the study drug. The main secondary endpoint was the occurrence of clinically relevant cerebral infarction at day 16 after study drug initiation. Other secondary endpoints included clinical outcome assessed on the modified Rankin Scale (mRS) and the Glasgow Outcome Scale-Extended (GOSE) at week 12 post-aSAH. Imaging and clinical endpoints were centrally adjudicated. Results: A total of 409 patients were randomized between February 2019 and May 2022 across 74 international sites. Three patients did not start study treatment and were not included in the analysis set. The occurrence of clinical deterioration due to DCI was 15.8% (32/202 patients) in the clazosentan group and 17.2% (35/204 patients) in the placebo group, and the difference was not statistically significant (relative risk reduction [RRR] 7.2%, 95% CI -42.6% to 39.6%, p = 0.734). A nonsignificant RRR of 34.1% (95% CI -21.3% to 64.2%, p = 0.177) was observed in clinically relevant cerebral infarcts treated with clazosentan (7.4%, 15/202) versus placebo (11.3%, 23/204). Rescue therapy was less frequently needed for patients treated with clazosentan compared to placebo (10.4%, 21/202 vs 18.1%, 37/204; RRR 42.6%, 95% CI 5.4%-65.2%). A nonsignificant relative risk increase of 25.4% (95% CI -10.7% to 76.0%, p = 0.198) was reported in the risk of poor GOSE and mRS scores with clazosentan (24.8%, 50/202) versus placebo (20.1%, 41/204) at week 12 post-aSAH. Treatment-emergent adverse events were similar to those reported previously. Conclusions: Clazosentan administered for up to 14 days at 15 mg/hour had no significant effect on the occurrence of clinical deterioration due to DCI. Clinical trial registration no.: NCT03585270 (ClinicalTrials.gov) EU clinical trial registration no.: 2018-000241-39 (clinicaltrialsregister.eu).
Convulsion During Intra-arterial Infusion of Fasudil Hydrochloride for the Treatment of Cerebral Vasospasm Following Subarachnoid Hemorrhage Commentary

Issom A. Awad,Liang Chen,Lion-Fu Zhou,Yuichi Tanaka

DOI: https://doi.org/10.2176/nmc.50.7

2010-01-01

Neurologia medico-chirurgica

Abstract:The incidence of convulsion and associated factors were retrospectively analyzed in 23 patients with symptomatic cerebral vasospasm following subarachnoid hemorrhage (SAH) who underwent a total of 31 intra-arterial infusion of fasudil hydrochloride (IAFH) procedures in 49 vessels. Fasudil hydrochloride was administered by superselective infusion via a microcatheter positioned at the proximal portion of the affected artery. Thirteen procedures were performed by manually controlled infusion of 30-75 mg fasudil hydrochloride (1.2-3.75 mg/ml) for approximately 10 minutes. Eighteen procedures were performed by continuous infusion of 60 mg fasudil hydrochloride (1.2 mg/ml) by infusion pump at a constant rate of 3 mg/min. Neurological improvement was observed after 18 of 22 procedures in patients with neurological deterioration due to vasospasm. Convulsion during IAFH developed in 4 patients, all treated by manual infusion (p < 0.05). The manual infusion method (p < 0.05) and infusion rate greater than 3 mg/min (p < 0.01) were significantly associated with the incidence of convulsion during IAFH. IAFH was effective for treating cerebral vasospasm following aneurysmal SAH. IAFH at a constant rate of 3 mg/min delivered by infusion pump improved the symptoms of cerebral vasospasm and prevented convulsions during IAFH.
Restriction of hypoxic membrane defect by glycine improves mitochondrial and cellular function in reoxygenated renal tubules.

G. Gronow,N. Klause,M. Mályusz

DOI: https://doi.org/10.1007/978-1-4615-1875-4_106

Advances in experimental medicine and biology

Abstract:
Delayed Symptomatic Vasospasm After Clipping Of An Unruptured Intracranial Aneurysm: Case Report And Literature Review

Changjiang Ou,Yili Chen,Shenghu Wang,Jun Mo,Weiwei Hu

2017-01-01

Abstract:Symptomatic vasospasm after clipping of unruptured intracranial aneurysms is a rare phenomenon. Herein, a case of delayed symptomatic vasospasm that developed after clipping of a middle cerebral artery aneurysm is reported. The experience in treatment is introduced, and relevant literature is reviewed to investigate the potential pathogenesis. A 50-year-old male was diagnosed with an unruptured aneurysm of the right middle cerebral artery and treated with uneventful clipping under general anesthesia. Motor aphasia and subsequent hemiparesis occurred on the 10th postoperative day. Emergent head computed tomography angiography indicated severe vasospasm of right MCA. The patient was treated with volume expansion, oral nimodipine, and antiplatelet therapy. Recovery at 4 months follow-up as assessed by Glasgow Outcome Scale was IV. The sequelae included moderate weakness in the left hand and mild weakness in the leg. Delayed symptomatic cerebral vasospasm may occur after uneventful clipping of unruptured intracranial aneurysms, causing severe outcomes. Treatments such as volume expansion, vasodilators administration, and intra-arterial angioplasty should be administered to ensure favorable outcomes.
09141 Executive Summary - Web Application Security

D. Boneh,Ú. Erlingsson,Martin Johns,B. Livshits

Abstract:Web applications are ubiquitous nowadays. Consequently, the field of Web application security is of ever rising significance. This Dagstuhl seminar was conducted to assemble researchers active in the domain to gain a first comprehensive overview of this young discipline in security research. From a content perspective, the topic was explored in a great variety of directions, including for instance Web browser-based security measures, language-based techniques, software engineering centric methods, run-time enforcement, static analysis, or formal approaches.
Severe cerebral edema induced by watershed shift after bypass in a patient with chronic steno-occlusive disease: a case report and short literature review

Yin Li,Yu-yu Wei,Yang Cao,Xiao-yang Lu,Yuan Yao,Lin Wang

DOI: https://doi.org/10.1186/s12883-020-01912-z

2020-09-05

BMC Neurology

Abstract:Abstract Background Carotid occlusive disease is a type of progressive disease resulting in ischemic stroke. Extracranial-intracranial bypass surgery represents a valid therapeutic option when medical treatment does not make effects. The appearance of cerebral edema following bypass is common during acute stage. Additionally, there are many causes of mild cerebral edema, such as hemodynamic changes, venous congestion and others. However, severe edema involving large brain tissue, which presents as reversible aphasia and hemiplegia, remains to be elucidated. Case presentation A 55-year-old man was admitted to the neurosurgery department for repeated dizziness for over a year and sudden onset of syncope 1 month prior, and he was diagnosed with carotid occlusive disease. After surgical contraindications were excluded, dual bypass and encephalo-duro-myo-synangiosis were performed. Although blood pressure and fluid management were strictly under control promptly after surgery, massive cerebral edema involving the left anterior cerebral artery and middle cerebral artery territories occurred from the 6th day after surgery. Additionally, no discernible cerebral infarction or hemorrhage occurred. Moreover, the cerebral blood flow of the middle cerebral artery displayed an early decrease followed by delayed elevation on the left side. Without restricting the spreading of cerebral edema, life-threatening cerebral herniation could develop at any time. Mannitol and furosemide were administered for impending cerebral herniation. The amelioration of symptoms was noticed on the 16th day after surgery. The patient felt relief on the 21st day after surgery. Digital subtraction angiography performed on the 180th day after surgery demonstrated the patency of dual anastomosed vessels, and the patient recovered without any permanent neurological deficit. Conclusion Based on changes in cerebral blood flow and reversible symptoms, the “watershed shift” phenomenon could explain such a severe deficit. However, this deficit was not the same as the classical presentation of the “watershed shift”, which involves a moderate amount of brain tissue and presents significant increases in cerebral blood flow. In addition to the “watershed shift”, a swollen temporal muscle may also participate in the progression of focal edema.

clinical neurology
Managing Patients With Sympathetic Crashing Acute Pulmonary Edema (SCAPE) Using the SCAPE Treatment Protocol: A Case Series

Ankur Verma,Sanjay Jaiswal,Anubhooti Mahawar,Maheshwar Lal,Saumya Gupta,Ruhima Begum

DOI: https://doi.org/10.7812/TPP/23.149

2024-06-14

Abstract:Pulmonary edema refers to the accumulation of excessive fluid in the alveolar walls and alveolar spaces of the lungs. It is a life-threatening condition with a high mortality rate and requires immediate assessment and management. Use of intravenous nitroglycerin has been advocated for such cases. The authors present a case series of 3 patients who presented to the emergency department with sympathetic crashing acute pulmonary edema (SCAPE) and were managed with high-dose intravenous nitroglycerin and bilevel positive airway pressure support using the SCAPE treatment protocol, leading to early correction of blood pressure, avoidance of endotracheal intubation, and no episodes of hypotension or rebound hypertension. The authors recommend emergency physicians utilize the SCAPE treatment protocol while managing patients with SCAPE.
Goal-directed Fluid Therapy Versus Conventional Fluid Therapy During Craniotomy and Clipping of Cerebral Aneurysm: A Prospective Randomized Controlled Trial

Summit D Bloria,Nidhi B Panda,Kiran Jangra,Hemant Bhagat,Banashree Mandal,Ketan Kataria,Rajeev Chauhan,Ankur Luthra,Shiv Lal Soni,Narender Kaloria,Shalvi Mahajan,Shamik Kr Paul,Shailesh Gupta,Sanket Agrawal,Navneet Singla

DOI: https://doi.org/10.1097/ANA.0000000000000769

2022-10-01

Abstract:Background: Fluid imbalance is common after aneurysmal subarachnoid hemorrhage and negatively impacts clinical outcomes. We compared intraoperative goal-directed fluid therapy (GDFT) using left ventricular outflow tract velocity time integral (LVOT-VTI) measured by transesophageal echocardiography with central venous pressure (CVP)-guided fluid therapy during aneurysm clipping in aneurysmal subarachnoid hemorrhage patients. Methods: Fifty adults scheduled for urgent craniotomy for aneurysm clipping were randomly allocated to 2 groups: group G (n=25) received GDFT guided by LVOT-VTI and group C (n=25) received CVP-guided fluid management. The primary outcome was intraoperative mean arterial pressure (MAP). Secondary outcomes included volume of fluid administered and several other intraoperative and postoperative variables, including neurological outcome at hospital discharge and at 30 and 90 days. Results: There was no difference in MAP between the 2 groups despite patients in group G receiving lower volumes of fluid compared with patients in group C (2503.6±534.3 vs. 3732.8±676.5 mL, respectively; P <0.0001). Heart rate and diastolic blood pressure were also comparable between groups, whereas systolic blood pressure was higher in group G than in group C at several intraoperative time points. Other intraoperative variables, including blood loss, urine output, and lactate levels were not different between the 2 groups. Postoperative variables, including creatinine, duration of postoperative mechanical ventilation, length of intensive care unit and hospital stay, and incidence of acute kidney injury, pneumonitis, and vasospasm were also comparable between groups. There was no difference in neurological outcome at hospital discharge (modified Rankin scale) and at 30 and 90 days (Extended Glasgow Outcome Scale) between the 2 groups. Conclusion: Compared with CVP-guided fluid therapy, transesophageal echocardiography-guided GDFT maintains MAP with lower volumes of intravenous fluid in patients undergoing clipping of intracranial aneurysms with no adverse impact on postoperative complications.

Cyclic AMP induced stimulation and inhibition of Ca2--uptake in rat cardiac sarcolemma vesicles.

On the ultraviolet absorption and the structure of motor anterior horn cells in the spinal cord from exhausted rabbits.

Dissociation of vasospasm-related morbidity and outcomes in patients with aneurysmal subarachnoid hemorrhage treated with clazosentan: A meta-analysis of randomized controlled trials: A review

Cardiopulmonary Events of the Elderly (≥75 Years) during Clazosentan Therapy after Subarachnoid Hemorrhage: A Retrospective Study from a Tertiary Stroke Center in Japan

Factors Influencing Discontinuation of Clazosentan Therapy in Elderly Patients with Aneurysmal Subarachnoid Hemorrhage: A Retrospective Study from a Japanese Single Center

Prophylactic management of cerebral vasospasm with clazosentan in real clinical practice: a single-center retrospective cohort study

Real-world data of clazosentan in combination therapy for aneurysmal subarachnoid hemorrhage: a multicenter retrospective cohort study

[Anatomo-histological aspects of renal tuberculosis treated with chemioantibiotic therapy].

Comparison of efficacy between clazosentan and fasudil hydrochloride-based management of vasospasm after subarachnoid hemorrhage focusing on older and WFNS grade V patients: a single-center experience in Japan

Initial clinical experience of vasodilatory effect of intra-cisternal infusion of magnesium sulfate for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage

Symptomatic Vasospasm Refractory to Clazosentan after Subarachnoid Hemorrhage of Ruptured Vertebral Artery Dissecting Aneurysm: Clinical Implications from Two Contrasting Cases

Transient convective burning of a periodic fuel-droplet array

[Postoperative Management of Aneurysmal Subarachnoid Hemorrhage]

REACT: a randomized trial to assess the efficacy and safety of clazosentan for preventing clinical deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage

Convulsion During Intra-arterial Infusion of Fasudil Hydrochloride for the Treatment of Cerebral Vasospasm Following Subarachnoid Hemorrhage Commentary

Restriction of hypoxic membrane defect by glycine improves mitochondrial and cellular function in reoxygenated renal tubules.

Delayed Symptomatic Vasospasm After Clipping Of An Unruptured Intracranial Aneurysm: Case Report And Literature Review

09141 Executive Summary - Web Application Security

Severe cerebral edema induced by watershed shift after bypass in a patient with chronic steno-occlusive disease: a case report and short literature review

Managing Patients With Sympathetic Crashing Acute Pulmonary Edema (SCAPE) Using the SCAPE Treatment Protocol: A Case Series

Goal-directed Fluid Therapy Versus Conventional Fluid Therapy During Craniotomy and Clipping of Cerebral Aneurysm: A Prospective Randomized Controlled Trial